COSCIENS Biopharma Inc. CSCIF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $7.50M, -21.8% YoY · Filed Mar 25, 2026
COSCIENS Biopharma Inc. (CSCIF) files with the SEC under industry code 2844, Perfumes, Cosmetics & Other Toilet Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.5 million and a net loss of $10.4 million. Free cash flow was -$9.2 million. As of Dec 31, 2025 it held $7.3 million in cash and investments and $2.1 million in total debt.
Revenue
$7.50M
-21.8% vs prior year
Net income
$-10.36M
+32.3% vs prior year
Operating cash flow
$-8.47M
+41.8% vs prior year
Free cash flow
$-9.18M
+41.6% vs prior year
EPS
$-3.27
+44.9% vs prior year
Dividend per share
None
Shares outstanding
3.18M
+1.4% vs prior year
Net cash
$5.16M
FY 2025
Operating margin
-142.5%
FY 2025
Company profile
- Industry
- Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
- Listed as
- CSCIF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Toronto, Ontario, Canada
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1113423
- Former names
- Aeterna Zentaris Inc. (until Aug 7, 2024); AETERNA LABORATORIES INC (until May 25, 2004)
Other Perfumes, Cosmetics & Other Toilet Preparations companies
- Colgate Palmolive Co CL
- Haleon plc HLN
- Estee Lauder Companies Inc EL
- e.l.f. Beauty, Inc. ELF
- Interparfums Inc IPAR
- Coty Inc. COTY
- EDGEWELL PERSONAL CARE Co EPC
- Oddity Tech Ltd ODD
All 22 Perfumes, Cosmetics & Other Toilet Preparations companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.5M | $9.6M | $7.1M | $14.6M | $5.3M |
| Operating income | -$10.7M | -$18.3M | -$4.6M | $4.3M | -$8.7M |
| Net income | -$10.4M | -$15.3M | -$3.5M | $3.4M | -$8.4M |
| Diluted EPS | -$3.27 | -$5.93 | -$1.89 | $1.86 | -$1.82 |
| Operating cash flow | -$8.5M | -$14.6M | -$2.6M | $5.2M | -$8.6M |
| Free cash flow | -$9.2M | -$15.7M | -$3.3M | $4.9M | -$8.6M |
| Total assets | $21.4M | $35.1M | $23.7M | $27.8M | $80.1M |
| Total liabilities | $17.6M | $21.9M | $2.7M | $4.0M | $27.1M |
| Cash and investments | $7.3M | $16.4M | $6.7M | $10.2M | $6.2M |
| Total debt | $2.1M | $2.3M | $1.7M | $1.9M | $161,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Jul 6, 2026 | Jul 6, 2026 |
| 6-K | Current report (foreign issuer) | Jun 23, 2026 | Jun 22, 2026 |
| 6-K | Current report (foreign issuer) | Jun 18, 2026 | Jun 18, 2026 |
| 6-K | Current report (foreign issuer) | May 20, 2026 | May 20, 2026 |
| 6-K | Current report (foreign issuer) | May 12, 2026 | May 12, 2026 |
| 6-K | Current report (foreign issuer) | May 12, 2026 | Mar 31, 2026 |
All 917 COSCIENS Biopharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.